BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Vanda Pharmaceuticals readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Vanda Pharmaceuticals's drugs run
 \, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07446439-1508@assetmemo.bio
DTSTAMP:20261121T005611Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:tradipitant: Phase 3 readout est. (NCT07446439)
DESCRIPTION:tradipitant\, phase 3.\nStudy: A Study to Evaluate Tradipitant 
 on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use\nEstimated p
 rimary completion: 1 December 2026. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/tradipitant#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07446439
URL:https://assetmemo.bio/drug/tradipitant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06138613-1508@assetmemo.bio
DTSTAMP:20261121T005611Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:tradipitant: Phase 3 readout est. (NCT06138613)
DESCRIPTION:tradipitant\, phase 3.\nStudy: Motion Delos: An Open Label Safe
 ty and Efficacy of Tradipitant in Participants Affected by Motion Sickness
 \nEstimated primary completion: 30 September 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/tradipitant#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06138613
URL:https://assetmemo.bio/drug/tradipitant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06961968-1732@assetmemo.bio
DTSTAMP:20261121T005611Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Iloperidone (Fanapt): Phase 3 readout est. (NCT06961968)
DESCRIPTION:Iloperidone (Fanapt)\, phase 3\, Schizophrenia.\nStudy: Randomi
 zed Withdrawal Study in Patients With Schizophrenia\nEstimated primary com
 pletion: November 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/iloperidone-fanapt#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06961968
URL:https://assetmemo.bio/drug/iloperidone-fanapt#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06953869-10836@assetmemo.bio
DTSTAMP:20261121T005611Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Hetlioz (tasimelteon): Phase 3 readout est. (NCT06953869)
DESCRIPTION:Hetlioz (tasimelteon)\, phase 3.\nStudy: Evaluating the Effects
  of Tasimelteon vs. Placebo in Treating Pediatric Insomnia\nEstimated prim
 ary completion: November 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/tasimelteon#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06953869
URL:https://assetmemo.bio/drug/tasimelteon#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06830044-9305@assetmemo.bio
DTSTAMP:20261121T005611Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Milsaperidone (VHX-896): Phase 3 readout est. (NCT06830044)
DESCRIPTION:Milsaperidone (VHX-896)\, phase 3\, Major Depressive Disorder.\
 nStudy: Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive T
 herapy in Patients With Major Depressive Disorder\nEstimated primary compl
 etion: March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/mi
 lsaperidone-vhx-896#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06830044
URL:https://assetmemo.bio/drug/milsaperidone-vhx-896#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07362017-1919@assetmemo.bio
DTSTAMP:20261121T005611Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Ponesimod: Phase 3 readout est. (NCT07362017)
DESCRIPTION:Ponesimod\, phase 3\, Psoriasis.\nStudy: Open Label Study to In
 vestigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chron
 ic Plaque Psoriasis\nEstimated primary completion: August 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/ponesimod#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07362017
URL:https://assetmemo.bio/drug/ponesimod#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07686081-1919@assetmemo.bio
DTSTAMP:20261121T005611Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Ponesimod: Phase 3 readout est. (NCT07686081)
DESCRIPTION:Ponesimod\, phase 3\, Ulcerative Colitis.\nStudy: Study to Eval
 uate the Efficacy and Safety of Ponesimod (VSP-128) in Patients With Moder
 ately to Severely Active Ulcerative Colitis\nEstimated primary completion:
  April 2029. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ponesimo
 d#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 686081
URL:https://assetmemo.bio/drug/ponesimod#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
